IRS2 and breast cancer: Irs-2-deficient PyV-MT-derived mammary tumor cells are significantly more sensitive to serum deprivation-induced apoptosis than wildtype tumor cells, and Irs-2-/- tumors also have a higher in situ level of apoptosis [75].